Technical Analysis for PDSB - PDS Biotechnology Corporation

Grade Last Price % Change Price Change
C 5.39 3.65% 0.19
PDSB closed up 3.65 percent on Friday, April 16, 2021, on 21 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical PDSB trend table...

Date Alert Name Type % Chg
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion 3.65%
Spinning Top Other 2.67%
Wide Bands Range Expansion 2.67%
180 Bullish Setup Bullish Swing Setup 1.89%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.89%
Inside Day Range Contraction 1.89%
Wide Bands Range Expansion 1.89%
Wide Bands Range Expansion 7.58%
Older End-of-Day Signals for PDSB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High 1 day ago
Outside Day 1 day ago
Up 3% 1 day ago
Up 2% 1 day ago
10 DMA Support 1 day ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


PDS Biotechnology Corporation Description

PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Oncology Cancers Cancer Immunotherapy Breast Cancer Prostate Cancer Treatment Of Breast Cancer Melanoma Lipid Immunotherapies Head And Neck Cancer Oncolytics Biotech Cervical Cancer Breast Cancers Anal Cancer

Is PDSB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 7.2967
52 Week Low 0.81
Average Volume 1,862,662
200-Day Moving Average 3.11
50-Day Moving Average 4.83
20-Day Moving Average 4.95
10-Day Moving Average 5.25
Average True Range 0.53
ADX 25.85
+DI 26.09
-DI 16.40
Chandelier Exit (Long, 3 ATRs ) 4.58
Chandelier Exit (Short, 3 ATRs ) 5.58
Upper Bollinger Band 5.89
Lower Bollinger Band 4.01
Percent B (%b) 0.73
BandWidth 38.00
MACD Line 0.21
MACD Signal Line 0.19
MACD Histogram 0.0254
Fundamentals Value
Market Cap 119.99 Million
Num Shares 22.3 Million
EPS 0.12
Price-to-Earnings (P/E) Ratio 46.07
Price-to-Sales 0.00
Price-to-Book 1.51
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.09
Resistance 3 (R3) 6.03 5.73 5.97
Resistance 2 (R2) 5.73 5.56 5.76 5.93
Resistance 1 (R1) 5.56 5.45 5.65 5.62 5.89
Pivot Point 5.27 5.27 5.31 5.30 5.27
Support 1 (S1) 5.10 5.09 5.18 5.16 4.89
Support 2 (S2) 4.80 4.98 4.83 4.85
Support 3 (S3) 4.63 4.80 4.81
Support 4 (S4) 4.69